“Advanced Wound Care Market set to grow to $13.8bn by 2024” says new Visiongain report

30 August 2019
Pharma

Visiongain has published a new pharma report Advanced Wound Care Market Forecast 2019-2029: Revenue Prospects by Products for Active Wound Care Dressings (Antimicrobial, Foam, Hydrocolloid, Film, Alginate, Hydrogel, Other), Wound Care Devices (NPWT, Ultrasound, Other) and Wound Care Biologics (Skin Replacement, Collagen-Based, Cell-Based, Other), Applications, End-Users and National Market.

Wound care is essential in improving the quality of life and overall well-being. The wound care industry is highly competitive and diverse with immense potential for growth. Drivers for growth include an increasingly ageing population, rising prevalence of diabetes and obesity, and growing patient awareness.

The number of patients suffering from all forms of chronic wounds is increasing worldwide at around 8% per year; this increasing incidence provides an avenue for substantial growth in the advanced wound care market over the coming years.

This report profiled the selected companies: Acelity, Coloplast, Mölnlycke, Organogenesis, Smith & Nephew, Cardinal Health, BSN Medical GmbH, Hollister, Inc. and other companies.

The lead analyst commented that "The advanced wound care market is expected to experience considerable growth over the forecast period. The main drivers for the growth include an increasingly ageing population, rising prevalence of diabetes and obesity, and growing patient awareness of products available. In the case of patients suffering from chronic wounds, wound care has become a necessity in order to reduce the risk of morbidity.

Due to the maturity of the active wound care dressings market, companies are moving away from the active wound dressings market into wound care devices and biologics. As more companies are entering this market, active wound dressings have become increasingly similar and lacking differentiation."

Notes for Editors If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Human Microbiome Therapeutics market set to grow to $1.6bn” by 2025 says new Visiongain report

The market for microbiome therapeutics is expected to commence around mid-2020 with the launch of new products relating to dermatology and gastrointestinal disorders.

04 December 2019

Read

“Global Next-Generation Biologics market set to grow to $42bn by 2024” says new Visiongain report

Technological developments in the next-generation biologics market will be the result of clinical development of multiple platforms in the next-generation antibody, antibody fragment and ALP sectors.

04 December 2019

Read

“Global Liquid Biopsy market set to grow to $4.9bn by 2024” says new Visiongain report

The main drivers for the growth include technological advancements such as development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

04 December 2019

Read

“Global nucleic acid isolation and purification market is anticipated to reach USD 8.16 Billion by 2030”, says Visiongain

Nucleic acid separation and purification is one of modern science and technology’s most complex and critical accomplishments.

29 November 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever